RBC Life Sciences, Inc.

RBC Life Sciences, Inc.

RBCL
RBC Life Sciences, Inc.US flagOther OTC
0.00
USD
- -
- -
1,549.00Market Cap
2004 Y
2005 Y
2006 Y
2007 Y
2008 Y
2009 Y
2010 Y
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
TTM
Revenue per Share
9.13
9.65
10.76
13.25
14.17
11.37
12.8
12.8
11.32
11.48
12.78
11.01
11.65
11.76
Basic EPS, GAAP
0.27
0.3
0.22
0.83
0.75
-0.15
0.25
-0.03
-0.16
-0.23
-0.27
-0.34
-0.34
-0.11
Free Cash Flow per Basic Share
0.43
0.35
0.79
1.81
-0.68
-0.45
0.17
-0.1
-0.16
0.01
-0.76
-2
- -
0.08
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
2.15
2.44
2.78
3.71
4.28
4.21
4.44
4.44
4.28
4.07
3.81
3.56
3.22
3.12
Tangible Book Value per Share
0.97
1.28
1.58
2.51
3.23
3.14
3.38
3.39
3.23
3.03
2.79
2.58
2.24
2.14
Basic Weighted Avg Shares
2
2
2
2
2
2
2
2
2
2
2
2
2
2
Sales/Revenue/Turnover
18
19
22
27
30
25
28
28
25
25
28
24
26
26
Operating Margin (%)
3.56
4.49
4.45
10.72
9.38
-0.64
3.71
-0.25
-3.6
-2.45
-2.21
-10.31
-2.59
-0.53
Depreciation Expense
1
1
1
- -
- -
- -
1
1
1
1
1
1
- -
- -
Net Income, GAAP
1
1
- -
2
2
- -
1
- -
- -
-1
-1
-1
-1
- -
Effective Tax Rate (%)
- -
4.32
38.92
37.06
39.63
- -
37.42
- -
- -
- -
- -
- -
- -
63.73
Profit Margin (%)
2.94
3.06
2.01
6.26
5.31
-1.34
1.98
-0.25
-1.44
-1.96
-2.13
-3.04
-2.93
-0.9
Working Capital
- -
1
2
4
5
5
6
6
5
4
3
5
4
4
LT Debt
3
3
3
2
2
2
2
2
1
1
1
- -
- -
- -
Total Equity
4
5
6
8
9
9
10
10
10
9
8
8
7
7
Return on Invested Capital (%)
8.72
10.59
7.05
19.68
16.02
- -
5.67
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
7.2
7.53
5.21
18.25
16.02
- -
5.67
- -
- -
- -
- -
- -
- -
-9.95
Return on Common Equity (%)
13.32
12.85
8.31
25.67
19.05
-3.6
5.84
-0.72
-3.73
-5.4
-6.91
-9.1
-10.08
-3.3

Capital Structure

FRC

in mil. unless spec.
Dec'16
Mar'17
Jun'17
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2
2
2
Market Capitalization
1
1
1

Working Capital

FRC

in mil. unless spec.
Dec'16
Mar'17
Jun'17
Total Current Assets
8
8
9
Cash, Cash Equivalents & STI
1
1
1
Accounts Receivable, Net
1
2
1
Inventories
4
4
6
Total Current Liabilities
3
4
5
Payables & Accruals
3
3
4
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.29%
-6.26%
-9.51%
Free Cash Flow
-661.3%
-1,254.79%
-100.15%
Net Income, GAAP
27.28%
97.89%
1.95%
Sales/Revenue/Turnover
2.57%
-1.47%
5.78%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2015
5
6
5
7
24
2016
5
6
7
7
26
2017
6
6
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2015
-0.25
-0.11
0.15
- -
-0.34
2016
-0.18
-0.08
0.05
- -
-0.34
2017
0.02
-0.05
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2015
- -
- -
- -
- -
- -
2016
- -
- -
- -
- -
- -
2017
- -
- -
- -
- -
- -

Company Description

CEO
David Price
Full Time Employees
89
Sector
Consumer Defensive
Industry
Household & Personal Products
Address
2301 Crown Court Irving TX United States of America 75038
IPO Date
Jan 3, 2000
Business
RBC Life Sciences, Inc. (OTC: RBCL) develops, manufactures, markets and distributes nutritional supplements and personal care products under the RBC Life brand, alongside advanced wound care and pain management solutions through its wholly owned subsidiary MPM Medical; its Nutritional Products segment offers herbs, vitamins, minerals, natural skin/hair/body care items, Stem-Kine dietary supplement, Microhydrin and Microhydrin Plus antioxidants, VitAloe blend, OliViva immune/cardiovascular beverage, Organic Spirulina, NeuroBright cognitive support, Colo-Vada Plus colon cleanser, HydraCel water enhancer, 24 Seven multivitamin/mineral, Immune 360 immune nourisher and Aloe Gelee soothing gel, marketed via independent distributors and licensing in North America, Southeast Asia and Australia; the Medical Products segment provides wound care for pressure/leg ulcers, cuts, burns and abrasions including cleansers, dressings, hydrogels, collagen, calcium alginates, moisture barriers, antimicrobials and Lidocaine hydrogel, plus radiation skin/tissue protection and pain/itch relief products sold under MPM Medical to U.S. hospitals, nursing homes, clinics and pharmacies through medical/surgical dealers and pharmaceutical distributors. Founded in 1988 and headquartered in Irving, Texas, the company targets wellness-seeking consumers and healthcare professionals across more than 30 countries with quality-assured products tested in-house and by independent labs. In January 2020, RBC Life Sciences received US Patent 8357422 for its NeuroBright supplement formulation supporting cognitive function, learning and memory based on an 18-month University of Texas at Dallas animal study demonstrating enhanced psychomotor abilities and longevity in test subjects.

Company News

  • Head-To-Head Analysis: Senestech (NASDAQ:SNES) vs. RBC Life Sciences (OTCMKTS:RBCL)

  • Owens & Minor (NYSE:OMI) versus RBC Life Sciences (OTCMKTS:RBCL) Head to Head Survey